21% sales growth for Boston Scientific:
This article was originally published in Clinica
Boston Scientific's total sales rose 21% to $1.9 billion in the year ended December 31. Excluding exchange rate effects, this represents an increase of 26%. In the fourth quarter, sales were $493 million, a 14% increase, or 19% excluding exchange rate effects. The US company will announce its full annual results in February.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.